PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31358485-11 2019 Median peripheral blood CD34+ cells at day 4 before BTZ administration was 16 per microliter and 15 hours later was 32 per microliter suggesting that administration of BTZ at peak G-CSF mobilization augments the mobilization effect of G-CSF. Bortezomib 168-171 CD34 molecule Homo sapiens 24-28 32876851-8 2020 Addition of bortezomib to Cy-GCSF mobilization showed a trend towards increased CD34 collection and reduced need for apheresis sessions. Bortezomib 12-22 CD34 molecule Homo sapiens 80-84 32124519-3 2020 RESULTS: We found a statistically significant correlation between the days from last dose of bortezomib and both CD34+ cells/kg yield on the first collection day and the overall collected CD34+ cells/kg (r = .466, P < .001, and r = .341, P = .03, respectively). Bortezomib 93-103 CD34 molecule Homo sapiens 113-117 32124519-3 2020 RESULTS: We found a statistically significant correlation between the days from last dose of bortezomib and both CD34+ cells/kg yield on the first collection day and the overall collected CD34+ cells/kg (r = .466, P < .001, and r = .341, P = .03, respectively). Bortezomib 93-103 CD34 molecule Homo sapiens 188-192 32124519-6 2020 Based on this, we developed a model to predict the total collected CD34+ cells/kg = 11.76 + 0.13 (timing in days of last dose of bortezomib) -0.1 (age) -1.39 (if female) -0.01 (>=PR) -1.35 (if prior radiation). Bortezomib 129-139 CD34 molecule Homo sapiens 67-71 24394665-0 2014 Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells. Bortezomib 0-10 CD34 molecule Homo sapiens 122-126 24394665-8 2014 The proteasome inhibitor bortezomib reversed the defective G-CSF-triggered granulocytic differentiation of CD34(+) cells from CN patients in vitro, an effect that was accompanied by restoration of LEF-1 protein levels and LEF-1 messenger RNA autoregulation. Bortezomib 25-35 CD34 molecule Homo sapiens 107-111 23357980-0 2013 Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Bortezomib 61-71 CD34 molecule Homo sapiens 126-130 23416210-0 2013 Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. Bortezomib 0-10 CD34 molecule Homo sapiens 49-53 23416210-2 2013 In this study, we questioned whether leukemic stem cell-enriched CD34(+) cells are sensitive to the proteasome inhibitor bortezomib. Bortezomib 121-131 CD34 molecule Homo sapiens 65-69 23416210-3 2013 Surprisingly, we observed in short-term and long-term culture assays that CD34(-) AML cells were more sensitive to bortezomib treatment compared with the CD34(+) AML cells at a clinical relevant dosage. Bortezomib 115-125 CD34 molecule Homo sapiens 74-78 23416210-5 2013 The better survival of CD34(+) AML cells upon bortezomib treatment was due to a persisting NF-kappaB activity that could be overcome by the IKK inhibitor BMS-345541. Bortezomib 46-56 CD34 molecule Homo sapiens 23-27 23416210-8 2013 MCL-1 accumulated in CD34(+) AML cells upon bortezomib treatment and inhibition of MCL-1 by shRNA, or Obatoclax, significantly improved the sensitivity of CD34(+) AML cells to bortezomib. Bortezomib 176-186 CD34 molecule Homo sapiens 155-159 18922853-0 2009 Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Bortezomib 151-161 CD34 molecule Homo sapiens 20-24 23391654-5 2013 Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Bortezomib 52-62 CD34 molecule Homo sapiens 94-98 23391654-6 2013 Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2x10(6)/kg, P=0.004). Bortezomib 78-88 CD34 molecule Homo sapiens 22-26 23038970-9 2012 The lowest blood CD34+ cell levels (1,586 -/+ 405 in 1 ml) were observed in Group 3 patients in whom bortezomib was used as first-line therapy. Bortezomib 101-111 CD34 molecule Homo sapiens 17-21 23038970-11 2012 The efficiency of mobilization proved to be high; more than 4.0.10(6)/kg of CD34+ cells were collected in all the patients with bortezomib-containing induction therapy, which allowed two autologous HSC transplantations to be carried out. Bortezomib 128-138 CD34 molecule Homo sapiens 76-80 21750922-5 2012 Despite their inhibition of CFU formation, perifosine, bortezomib and lenalidomide induced only slight or moderate cytotoxicity in CD34(+) selected HPC, as assessed using different assays such as flow cytometry-based detection of activated caspases and immunohistochemistry studies (e.g., Ki-67 staining). Bortezomib 55-65 CD34 molecule Homo sapiens 131-135 18922853-6 2009 Bortezomib up-regulated TRAIL receptor expression on quiescent CD34(+) CML cells, and further enhanced their susceptibility to cytotoxicity by in vitro expanded donor NK cells. Bortezomib 0-10 CD34 molecule Homo sapiens 63-67 18166786-4 2008 DESIGN AND METHODS: We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and fresh cells from 28 AML patients including CD34(+) and CD34(-) cases. Bortezomib 80-90 CD34 molecule Homo sapiens 157-161 18166786-4 2008 DESIGN AND METHODS: We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and fresh cells from 28 AML patients including CD34(+) and CD34(-) cases. Bortezomib 80-90 CD34 molecule Homo sapiens 169-173 18166786-8 2008 The apoptotic activity of bortezomib on fresh CD34(+) blast cells from patients was similar to that observed on CD34(-)blast cells. Bortezomib 26-36 CD34 molecule Homo sapiens 46-50 18166786-9 2008 Importantly, bortezomib was significantly more active than doxorubicin in the immature CD34(+) cells, while there were no differences in its action on CD34(-) cells. Bortezomib 13-23 CD34 molecule Homo sapiens 87-91 17229337-11 2006 Bortezomib/DT-PACE compared favorably with DT-PACE with regard to leukapheresis days, total CD34+ cell collection, and engraftment. Bortezomib 0-10 CD34 molecule Homo sapiens 92-96 18024285-5 2007 RESULTS: Low-concentration STI571, As2O3 or Velcade all dose-dependently inhibited bcr/abl+-CD34+ cell proliferation without obvious apoptosis-inducing effects. Bortezomib 44-51 CD34 molecule Homo sapiens 92-96 34563457-4 2021 However, by adding plerixafor to bortezomib and cyclophosphamide, collected CD34-positive cells were increased six-fold compared to the previous day. Bortezomib 33-43 CD34 molecule Homo sapiens 76-80